AngioDynamics, Inc.

How big is AngioDynamics, Inc.?

As of Jun 18, AngioDynamics, Inc. has a market capitalization of 416.33 million, with net sales of 283.31 million and a net profit of -41.40 million over the last four quarters. Shareholder's funds are 205.59 million, and total assets are 317.67 million.

Market Cap: <BR>As of Jun 18, AngioDynamics, Inc. has a market capitalization of 416.33 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, AngioDynamics, Inc. reported net sales of 283.31 million and a net profit of -41.40 million.<BR><BR>Balance Sheet Snapshot: <BR>As of May 24, the company's shareholder's funds amounted to 205.59 million, while total assets were reported at 317.67 million.

What does AngioDynamics, Inc. do?

AngioDynamics, Inc. designs and manufactures medical devices for vascular access, peripheral vascular disease treatment, and oncology. As of February 2025, it reported net sales of $72 million and a net loss of $4 million, with a market cap of $416.33 million.

Overview:<BR>AngioDynamics, Inc. designs, manufactures, and sells a range of medical, surgical, and diagnostic devices for vascular access, treatment of peripheral vascular disease, and use in oncology and surgical settings within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 72 Million (Quarterly Results - Feb 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Feb 2025) <BR>Market cap: USD 416.33 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.23 <BR>Return on Equity: -10.23% <BR>Price to Book: 2.24<BR><BR>Contact Details:<BR>Address: 14 Plaza Dr, Latham NY 12110-2166 <BR>Tel: ['1 518 7981215', '1 518 7951408'] <BR>Fax: 1 518 7951401 <BR>Website: https://www.angiodynamics.com/

Who are in the management team of AngioDynamics, Inc.?

As of March 2022, the management team of AngioDynamics, Inc. includes Mr. Howard Donnelly (Independent Chairman), Mr. James Clemmer (President and CEO), and several independent directors: Ms. Eileen Auen, Mr. Wesley Johnson, Ms. Karen Licitra, Mr. Dennis Meteny, and Ms. Jan Reed. This team oversees the company's governance and strategic direction.

As of March 2022, the management team of AngioDynamics, Inc. includes the following individuals:<BR><BR>- Mr. Howard Donnelly, Independent Chairman of the Board<BR>- Mr. James Clemmer, President, Chief Executive Officer, and Director<BR>- Ms. Eileen Auen, Independent Director<BR>- Mr. Wesley Johnson, Independent Director<BR>- Ms. Karen Licitra, Independent Director<BR>- Mr. Dennis Meteny, Independent Director<BR>- Ms. Jan Reed, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Should I buy, sell or hold AngioDynamics, Inc.?

Is AngioDynamics, Inc. overvalued or undervalued?

As of January 5, 2024, AngioDynamics, Inc. is considered overvalued with a risky outlook due to negative return metrics and high valuation ratios, despite a recent 1-year return of 44.87% that outperformed the S&P 500.

As of 5 January 2024, AngioDynamics, Inc. has moved from a fair to a risky valuation grade, indicating a deteriorating outlook. The company appears to be overvalued given its current price of 11.01, especially when considering its negative P/E ratio and poor return metrics, such as a ROCE of -18.35% and a ROE of -10.23%. The Price to Book Value stands at 2.44, which is relatively high compared to peers like CareDx, Inc. with a P/E of -27.91 and Organogenesis Holdings, Inc. with a P/E of 608.59, suggesting that AngioDynamics may not be justifying its valuation in the current market.<BR><BR>In terms of recent performance, AngioDynamics has shown a 1-year return of 44.87%, significantly outperforming the S&P 500's return of 17.14%, which may create a misleading perception of its value. However, the company's long-term performance is concerning, with a 3-year return of -49.66% compared to the S&P 500's 70.41%. Overall, the combination of high valuation ratios and negative returns suggests that AngioDynamics, Inc. is currently overvalued.

Is AngioDynamics, Inc. technically bullish or bearish?

As of August 29, 2025, AngioDynamics, Inc. shows a neutral technical trend with mixed indicators, outperforming the S&P 500 over the past month and year, but underperforming over the 3- and 5-year periods.

As of 29 August 2025, the technical trend for AngioDynamics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, and the KST shows a bearish weekly signal but a bullish monthly signal. The Dow Theory indicates a mildly bullish weekly stance but a mildly bearish monthly one. The OBV is mildly bullish weekly and mildly bearish monthly. <BR><BR>In terms of performance, AngioDynamics has outperformed the S&P 500 over the past month (25.40% vs. 2.33%) and year (44.87% vs. 17.14%), but has significantly underperformed over the 3-year and 5-year periods.